Drug Type Small molecule drug |
Synonyms Compound Loratadine, Loratadine and Pseudoephedrine, Loratadine and Pseudoephedrine sulfate + [10] |
Mechanism ADRA1 agonists(Adrenergic receptor alpha-1 agonists), ADRA2 agonists(Adrenergic receptors alpha-2 agonists), H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Nov 1994), |
Regulation- |
Molecular FormulaC22H23ClN2O2 |
InChIKeyJCCNYMKQOSZNPW-UHFFFAOYSA-N |
CAS Registry79794-75-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Loratadine/Pseudoephedrine Sulfate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Common Cold | US | 23 Aug 1996 | |
Fever | US | 23 Aug 1996 | |
Hypersensitivity | US | 23 Aug 1996 | |
Rhinitis, Allergic, Seasonal | US | 14 Nov 1994 | |
Upper respiratory tract allergy | US | 14 Nov 1994 |
Phase 4 | 82 | Loratadine-Pseudoephedrine tablet | jfhanpsdeu(pjwvlxuvdx) = scllssdrff voekfbqltz (nisnxhyube ) | - | 14 May 2021 | ||
jfhanpsdeu(pjwvlxuvdx) = ebkazjtnsd voekfbqltz (nisnxhyube ) |